Search
for
Sort by
Research
270-300 / 1000+ resultsresearch Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Finasteride
research Diffuse plate-like sheets of desquamation
The rash resolved after stopping ponatinib.
research Rivaroxaban-induced hair loss
Rivaroxaban may cause hair loss.
research SnapshotDx Quiz: September 2018
Tofacitinib may help regrow hair in alopecia areata patients.
research Evaluation of Therapeutic Potential of a Selective 5α-reductase Inhibitor against Glioblastoma: Molecular Docking and In Vitro Insights
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research News in brief ???
Dicentrine reduced heart disease risk factors in rats, T-588 protected mice brains without side effects, Provir blocked herpes virus and lessened mouse symptoms, and LY191704 could treat hair loss and prostate issues.
research A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
A small group of slow-growing cells causes basal cell carcinoma to return after treatment.
research A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily, High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
research Multimodal therapeutic approach for a severe case of kaposiform lymphangiomatosis from procedural interventions to targeted therapies
Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research Gefitinib: an adverse effects profile
Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
research 575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies
INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
research A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro
AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
research Flurandrenolide
research Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
research Phosphodiesterase inhibitors used in androgenic alopecia as a possible risk factor for testicular tumor
research Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.
research Growth inhibition of mouse skin tumor by serine protease inhibitor ONO-3403.
ONO-3403 effectively reduces mouse skin tumor growth without side effects.
research Финастерид в профилактике прогрессирования рака предстательной железы
Finasteride reduces prostate size, improves urination, and slows prostate cancer progression.